Results 81 to 90 of about 12,135 (165)

Population pharmacokinetics of lumefantrine in pregnant and non‐pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 911-921, March 2026.
Aim This study intends to assess the pharmacokinetic properties and treatment response of lumefantrine in pregnant and non‐pregnant women with uncomplicated Plasmodium falciparum malaria infection in Western Kenya. Methods Seventy‐five women with uncomplicated P.
Elizabeth Juma, Junjie Ding, Martin Ongas, Nelly Koskei, Kevin Onyango, Florence Oloo, Rashid Aman, Gilbert Kokwaro, Joel Tarning, Bernhards Ogutu   +9 more
wiley   +1 more source

Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.

, 2013
BACKGROUND: Artemisinin-based combination therapy (ACT) reduces the potential for malaria transmission, compared with non-ACTs. It is unclear whether this effect differs between ACTs.
Sauerwein, Robert W, Drakeley, Chris J, Bousema, Teun, Kavishe, R.A., Kavishe, Reginald A, Hallett, Rachel L, Mweresa, Collins K, Hermsen, C.C., Sauerwein, R.W., Shekalaghe, S., Manjurano, Alphaxard, Omar, S.A., Shekalaghe, Seif A., Sawa, Patrick, Sutherland, Colin J, Baidjoe, Amrish Y, Yussuf, R.U., Mweresa, C.K., Omar, Sabah A., Okell, L., Okell, Lucy, Hermsen, Cornelus C., Schallig, Henk DFH, Bousema, T., Manjurano, A., Baidjoe, A.Y., Mweresa, Collins K., Hallett, R.L., Beshir, Khalid B., Beshir, Khalid B, Shekalaghe, Seif A, Beshir, K.B., Drakeley, Chris J., Kavishe, Reginald A., Omar, Sabah A, Sutherland, Colin J., Yussuf, Rahma U, Sawa, P., Baidjoe, Amrish Y., Schallig, H.D., Yussuf, Rahma U., Drakeley, C., Hermsen, Cornelus C, Sutherland, C.J., Sauerwein, Robert W., Hallett, Rachel L., Schallig, Henk D.F.H.   +46 more
core   +1 more source

Artemisinin‐Based Combination Therapies in East Africa: A Systematic Review of Quality, Clinical Efficacy, and Regulatory Progress Towards Sustainable Malaria Control

Tropical Medicine &International Health, Volume 31, Issue 3, Page 254-273, March 2026.
ABSTRACT Background Malaria is a major public health issue in East Africa, leading to widespread illness and fatalities, especially among vulnerable populations such as children under 5 years of age and pregnant women. Artemisinin‐based combination therapies (ACTs) are the primary treatment modality; however, their efficacy is undermined by the ...
Yesuneh Tefera Mekasha, Addisu Afrassa Tegegne, Tapfumanei Mashe, Million Girma, Gemmechu Hasen, Sileshi Belew   +5 more
wiley   +1 more source

Artemether-lumefantrine for treating uncomplicated falciparum malaria.

, 2003
BACKGROUND: Artemether-lumefantrine is being promoted by the World Health Organization for treating uncomplicated malaria. It is expensive. We sought evidence of its superiority over existing treatment regimens.
Omari, A. A., Gamble, Carrol, Garner, P.; id_orcid   +2 more
core   +1 more source

Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study

Malaria Journal, 2007
Background Zambia was the first African country to change national antimalarial treatment policy to artemisinin-based combination therapy – artemether-lumefantrine.
Chanda Pascalina, Hamer Davidson H, Sipilanyambe Nawa, Ndhlovu Mickey, Zurovac Dejan, Simon Jon L, Snow Robert W   +6 more
doaj   +1 more source

Antimalarial Polyethylene Glycol–Lumefantrine Conjugates: Synthesis and Effect of Linker Chemistry on Drug Release

Advanced Therapeutics, Volume 9, Issue 2, February 2026.
Research into advanced therapeutics for malaria are rare. We investigate how linker chemistry governs the release kinetics of the antimalarial lumefantrine from polyethylene glycol conjugates. A clear correlation between diacid linker length and drug release rate is established, enabling rational design of conjugates with controlled release.
Thenesia R. Govender, William M. R. Matshe, Nokuthula Dube, Zamani E. D. Cele, Aurelia A. Williams, Lynne A. Pilcher, Mohammed O. Balogun   +6 more
wiley   +1 more source

Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana

Malaria Journal, 2012
Background In Guyana, chloroquine + primaquine is used for the treatment of vivax malaria. A worldwide increase of chloroquine resistance in Plasmodium vivax led to questioning of the current malaria treatment guidelines. A therapeutic efficacy study was
Eibach Daniel, Ceron Nicolas, Krishnalall Karanchand, Carter Keith, Bonnot Guillaume, Bienvenu Anne-Lise, Picot Stéphane   +6 more
doaj   +1 more source

Severe Plasmodium knowlesi Malaria in a Tertiary Care Hospital, Sabah, Malaysia

Emerging Infectious Diseases, 2011
The simian parasite Plasmodium knowlesi causes severe human malaria; the optimal treatment remains unknown. We describe the clinical features, disease spectrum, and response to antimalarial chemotherapy, including artemether-lumefantrine and artesunate ...
Timothy William, Jayaram Menon, Giri S. Rajahram, Leslie Chan, Gordon Ma, Samantha Donaldson, Serena Khoo, Charlie Fredrick, Jenarun Jelip, Nicholas M. Anstey, Tsin Wen Yeo   +10 more
doaj   +1 more source

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 317-322, January 2026.
In silico pharmacokinetic–pharmacodynamic (PK–PD) models are used to inform dose optimisation in antimalarial drug development. Here the PK–PD models capture the change in parasite count over time because of exposure to antimalarial drug(s). For current deterministic PD models, simulated parasite numbers decline proportionally during treatment ...
Meg K. Tully, Robert J. Commons, Julie A. Simpson, David J. Price   +3 more
wiley   +1 more source

Malaria Screening and Treatment in Hematopoietic Cell Transplant Donors and Sickle Cell Disease Candidates/Recipients: A Case Series Using Malaria Polymerase Chain Reaction Testing and a Literature Review

Transplant Infectious Disease, Volume 28, Issue 1, January/February 2026.
Malaria polymerase chain reaction (PCR) testing is more sensitive than conventional diagnostics. Routine PCR screening of at‐risk asymptomatic hematopoietic cell donors and transplant candidates may prevent unnecessary deferrals or treatment. In our experience, PCR negativity during screening or after treatment supports donor/candidate eligibility ...
Mary M. Czech, Sanchita Das, Emily Limerick, Courtney Fitzhugh, Matthew Hsieh, Jennifer Cuellar‐Rodriguez   +5 more
wiley   +1 more source